Lyrica Significantly Reduced Pain And Improved Other Symptoms Of Post-Traumatic Peripheral Nerve Pain, New Data Show Patients suffering from post-traumatic peripheral nerve pain treated with Lyrica® (pregabalin) capsules CV experienced significantly reduced pain compared to those taking placebo, according to new data presented today at the American Academy of Neurology annual meeting. The data also showed that patients treated with Lyrica reported less pain interference with sleep and were significantly more likely to report feeling better overall at the end of the study compared with placebo.
Source: www.medicalnewstoday.comSchering-Plough Highlights Hepatitis C Clinical Data Presentations At The European Association For The Study Of The Liver (EASL) Annual Meeting Schering-Plough Corporation (NYSE: SGP) reported that final results of three large PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding questions in the hepatitis C research community and provide important insights. The results of the studies, involving a total of more than 2,700 patients, were presented at the 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting.
Source: www.medicalnewstoday.comEarthly Delights™ Launches Their Stevia Sweetened Juice Blends Featuring a Full Day's Serving of Antioxidants Three new blends from Earthly Delights™ with Stevia are packed with antioxidants, each boasting an antioxidant/ ORAC Value (oxygen radical absorbance capacity) of 5,000 per serving, along with 100% of the recommended daily allowance of Vitamin C, and 50% of the sugar compared to pure Pomegranate juice. (PRWeb May 2, 2009)
Read the full story at http://www.prweb.com/releases/2009/05/prweb2376994.htm
Source: www.prweb.comMedicine Woman Is Able to Help Many People by Giving HOPE Brenda Bates Medicine Woman/Spiritual Leader is back to having a home based business. (PRWeb May 1, 2009)
Read the full story at http://www.prweb.com/releases/2009/05/prweb2379264.htm
Source: www.prweb.comNovartis Investigational Adjuvanted (MF59) Pre-pandemic Avian Influenza Vaccine Aflunov® Shows Long Lasting, cross-protective Immune Response A study published this week in the Proceedings of the National Academy of Sciences of the United States of America shows that Aflunov®, the Novartis investigational pre-pandemic avian influenza vaccine formulated with Novartis' proprietary MF59® adjuvant, can elicit a broadly cross-reactive immune response covering all known H5N1 antigenic variants, even when that booster dose is administered six years after the initial priming dose.
Source: www.medicalnewstoday.comAccolades PR - Giving Cancer the Bird at Flamingo-a-Go-Go Public Relations firm promotes Austin's Hippest Fundraising Soir�e (PRWeb May 1, 2009)
Read the full story at http://www.prweb.com/releases/cancer_support/non_profit/prweb2380264.htm
Source: www.prweb.comPeople Of Higher Socioeconomic Status Choose Better Diets But Pay More Per Calorie As people become more educated, studies have demonstrated that they tend to choose foods that are lower in calories but higher in nutrients. They also pay more. In a study published in the May 2009 issue of the Journal of the American Dietetic Association, researchers from the University of Washington compared the eating habits and food costs of a sample of 164 adults in the Seattle, Washington area. The energy density of the
diet (i.e.
Source: www.medicalnewstoday.comJoy of Spa - Instant, Online Delivery of Mother's Day Spa Gifts - Last-minute, Long-distance Spa Gift Options Joy of Spa has launched, just in time to help celebrate Mother's Day. Providing the gift of spa - instantly- from thousands of spas, Joy of Spa makes pleasing that special Mom in your with life a beautiful, informed and relaxing experience. Shopping for Mom has never been easy; giving the perfect Mother's Day spa gift means delivering a heartfelt, experiential, and yes, convenient (for the buyer!) gift this year. (PRWeb May 2, 2009)
Read the full story at http://www.prweb.com/releases/2009/05/prweb2384384.htm
Source: www.prweb.comPhase III Trial Of Nexavar® In Chemotherapy-Naive Patients With Advanced Melanoma Does Not Meet Primary Endpoint Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that a Phase III trial evaluating Nexavar® (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was stopped early following a planned interim analysis by an independent Data Monitoring Committee (DMC). The trial was sponsored by the National Cancer Institute and led by the Eastern Cooperative Oncology Group (ECOG) under a Clinical Trials Agreement between NCI and Bayer and Onyx.
Source: www.medicalnewstoday.comPersonal Care Non-Acetone Nail Polish Remover Nationwide recall issued because of the potential for the product to cause chemical burns to the fingers of users.
Source: www.fda.gov
# posted by Network @ 5:46 PM
